HACD2: Key Enzyme in Citric Acid Cycle (G201562)

Target Name: HACD2

NCBI ID: G201562

HACD2

Other Name(s): Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2 (isoform b) | PTPLB | HACD2_HUMAN | Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2 | protein-tyrosine phosphatase-like member B | 3-hydroxyacyl-CoA dehydratase 2, transcript variant 2 | protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b | Protein-tyrosine phosphatase-like member B | 3-hydroxyacyl-CoA dehydratase 2 | very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] dehydratase 2 | HACD2 variant 2

HACD2: Key Enzyme in Citric Acid Cycle

HACD2, or Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2 (isoform b), is a protein that is expressed in various tissues throughout the body. It is involved in the metabolism of fatty acids, including the production of ketone bodies, which are important energy sources for the body.

HACD2 is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. The citric acid cycle is a central metabolic pathway that is responsible for generating energy from food inputs in the form of glucose. It is a highly regulated pathway that is involved in the production of a wide range of molecules, including amino acids, nucleotides, and energy in the form of ATP.

HACD2 is a key enzyme that is involved in the production of the last step of the citric acid cycle, the 尾-hydroxyacetyl-CoA (尾-HAC) step. This step is critical for the production of ketone bodies, which are the end products of the citric acid cycle. Ketone bodies are important energy sources for the body and are involved in a wide range of physiological processes, including energy metabolism, inflammation, and cellular signaling.

HACD2 is also involved in the regulation of the citric acid cycle. It is known to play a role in the negative regulation of the cycle, which means that it tends to slow down the rate at which the cycle produces ATP. This is important for maintaining the stability of the cellular pH and for maintaining the integrity of the cellular membrane.

HACD2 is also expressed in various tissues and is involved in the metabolism of fatty acids. It is a key enzyme in the production of fatty acids, including omega-3 fatty acids, which are important for maintaining cellular health and function. It is also involved in the production of arachidonic acid, which is a pro-inflammatory compound that is involved in inflammation.

HACD2 is a potential drug target and may be a biomarker for a variety of diseases. For example, it is known to be involved in the development and progression of certain diseases, such as cancer. It is also involved in the regulation of cellular signaling, which means that it may be involved in the development of a wide range of diseases.

In conclusion, HACD2 is a protein that is involved in the metabolism of fatty acids and is a key enzyme in the citric acid cycle. It is a potential drug target and may be a biomarker for a variety of diseases. Further research is needed to fully understand its role in the cell and its potential as a therapeutic target.

Protein Name: 3-hydroxyacyl-CoA Dehydratase 2

Functions: Catalyzes the third of the very long-chain fatty acids (VLCFA) elongation four-step cycle (condensation, reduction, dehydration, and reduction). This endoplasmic reticulum-elongation process is characterized by the addition of two carbons to the lipid chain through each cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of elongation. Therefore, it participates in the production of various VLCFAs involved in multiple biological processes as precursors of membrane lipids and lipid mediators

The "HACD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HACD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets